Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.
This lecture by prof. Erik Stroes was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RATargeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
Prof. Johannes Mann, MD
- Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RADiabetes and CKD: is it all about managing glucose?
Prof. Melanie Davies, MD